Earnings Releases·Nov 12, 2026, 4:10 PM ET

Lineage Cell Therapeutics — Third Quarter 2026 Earnings Summary

Total revenues decreased 59% year-over-year to $1.5 million from $3.7 million in Q3 2025, while operating expenses rose 17% to $8.8 million; the company reported a net income of $4.2 million ($0.02 EPS) compared to a net loss of $29.8 million in the prior year period, driven by a $12.0 million non-cash gain on warrant liability remeasurement.
The company acquired NeuroAirmid Therapeutics, Inc., adding the clinical-stage HUNT1 Huntington's disease asset to its pipeline, with the REGEN4HD trial now enrolling and supported by a CIRM grant.
Cash, cash equivalents, and marketable securities totaled $45.2 million as of September 30, 2026, providing a runway to support operations through Q2 2028, though the company acknowledges potential capital needs prior to that date.
Key development milestones include expected initial preclinical data for the COR1 program in Q1 2027, a scheduled meeting with the Danish Medicines Agency for the ReSonance program in Q4 2026, and the completion of cGMP material manufacturing for ReSonance.
Operational risks include potential disruptions to the OpRegen (GAlette) study and Jerusalem manufacturing due to the ongoing 2026 Iran War and regional conflict, alongside the uncertainty of Genentech's discretion over the advancement of the OpRegen program.